TD Cowen Initiates Protagonist Therapeutics(PTGX.US) With Buy Rating, Announces Target Price $65
TD Cowen analyst Tara Bancroft initiates coverage on $Protagonist Therapeutics(PTGX.US)$ with a buy rating, and sets the target price at $65.According to TipRanks data, the analyst has a success
Express News | Protagonist Therapeutics Inc : TD Cowen Initiates Coverage With Buy Rating; Target Price $65
The 8.6% Return This Week Takes Protagonist Therapeutics' (NASDAQ:PTGX) Shareholders Five-year Gains to 231%
H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $50
H.C. Wainwright analyst Douglas Tsao maintains $Protagonist Therapeutics(PTGX.US)$ with a buy rating, and adjusts the target price from $40 to $50.According to TipRanks data, the analyst has a
Analysts Offer Insights on Healthcare Companies: Walgreens Boots Alliance (WBA), Belite Bio, Inc. ADR (BLTE) and Protagonist Therapeutics (PTGX)
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines
Truist Financial Initiates Protagonist Therapeutics(PTGX.US) With Buy Rating, Announces Target Price $60
Truist Financial analyst Srikripa Devarakonda initiates coverage on $Protagonist Therapeutics(PTGX.US)$ with a buy rating, and sets the target price at $60.According to TipRanks data, the analyst
Truist Initiates Protagonist Therapeutics at Buy With $60 Price Target
Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
Protagonist Therapeutics Price Target Cut to $43.00/Share From $45.00 by JMP Securities
Protagonist Therapeutics Is Maintained at Market Outperform by JMP Securities
HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $40
Protagonist Therapeutics Analyst Ratings
Express News | Protagonist Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $40 From $38
JMP Securities Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $43
JMP Securities analyst Jonathan Wolleben maintains $Protagonist Therapeutics(PTGX.US)$ with a buy rating, and maintains the target price at $43.According to TipRanks data, the analyst has a success
Capital One Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $48
Capital One Financial analyst Tim Chiang maintains $Protagonist Therapeutics(PTGX.US)$ with a buy rating, and maintains the target price at $48.According to TipRanks data, the analyst has a success
JMP Securities Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Cuts Target Price to $43
JMP Securities analyst Jonathan Wolleben maintains $Protagonist Therapeutics(PTGX.US)$ with a buy rating, and adjusts the target price from $45 to $43.According to TipRanks data, the analyst has a
Buy Rating Affirmed for Protagonist Therapeutics on Strong Pipeline and Strategic Partnerships
Protagonist Therapeutics | 10-Q: Q2 2024 Earnings Report
Protagonist Says Cash And Equivalents Of $595.4M As Of June 30, 2024, Anticipated To Provide Cash Runway Through End Of 2027